Brazil’s Fiocruz releases 192 drug batches for SUS during Q1’19

Brazil’s Institute of Technology and Pharmaceuticals (Farmanguinhos) of the Oswaldo Cruz Foundation (Fiocruz) released 192 drug batches for the Unified Health System (SUS) during Q1’19, totalling 26 million units. Some of these products were the result of technology transfer deals through Productive Development Partnerships (PDPs) with pharmaceutical companies.

Medicines produced include antiretrovirals lamivudine, lamivudine + zidovudine, efavirenz, nevirapine, and tenofovir + lamivudine, as well as antimalarial chloroquine, tuberculosis treatment isoniazid, antiviral oseltamivir, and vitamin A.


Related news
China-based Sino Biopharmaceutical Ltd (HKEX.01177) has announced marketing approval in the European Union (EU) for its subsidiary Chia Tai Tianqing Pharmaceutical Group Co. Ltd’s tenofovir disoproxil fumarate (TDF).
The trade war between the United States and China is gaining momentum, after a brief hiatus.
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (600521.SH) announced that its generic version of the HIV/AIDS drug efavirenz has been included in the “Listed Drugs Catalogue of China", indicating that said drug has passed generic quality consistency evaluation (GQCE) testing. Efavirenz, was originally developed by Merck & Co., to treat adults, adolescents, and children infected with human immunodeficiency virus (HIV)-1 virus in combination with other antiviral drugs.
Scientists at Mexico’s Autonomous University of Nuevo Leon (UANL) and the Biotechnology and Nanotechnology Research Center (CIByN) have developed a method to boost the antibiotic effect of conventional tuberculosis (TB) drugs.
ViiV Healthcare, an HIV/AIDS-focused joint venture (JV) created by GlaxoSmithKline (GSK) and Pfizer, last week announced approval from the U.S. FDA for its antiretroviral Dovato (dolutegravir + lamivudine), which was devised by an Argentine-based team of researchers led by Pedro Cahn at the University of Buenos Aires (UBA) and the Fundación Huésped.
Recent news
Argentina-based Laboratorios Bagó this week opened a new injectable drugs production facitlity in Buenos Aires.
Brazil’s health technology company WW8 last week launched its platform Athimos (, a medical communications and patient records system.
Brazil’s Ministry of Health has requested the Oswaldo Cruz Foundation (Fiocruz) to supply the Unified Health System (SUS) with immunosuppressant tacrolimus for kidney and liver transplant patients.
Cuba’s state-run biopharmaceutical group BioCubaFarma this week presented its products to Chile’s biotechnology and pharmaceutical industry.
Beijing-headquartered Contract Research Organization (CRO) Joinn Laboratories (China) Co., Ltd (603127.SH) has entered into an equity purchase agreement with U.S.-based pre-clinical CRO Biomedical Research Models Inc​.
The National Health Commission released its annual statistical round-up of China’s national health system during 2018.
Shanghai-based Allist Pharmaceuticals Inc., raised RMB 1.18 billion (USD 162 million) via a Series A financing round led by Shenzhen Shiyu Investment Management Co., Ltd​.